Cytokine network: New targeted therapy for pancreatic cancer

Current Pharmaceutical Design

Volumn 18, Issue 17, 2012, Pages 2416-2419

  Matsuo, Yoichi ^a   Takeyama, Hiromitsu ^a   Guha, Sushovan ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Cytokine; Pancreatic cancer; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CYTOKINE RELEASE; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84860454409     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128112092416     Document Type: Review

References (71)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
2. Niedergethmann M, Alves F, Neff JK, et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007; 16: 1432-40.
3. Matsuo Y, Ochi N, Sawai H, et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 2009; 124: 853-61.
4. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001; 345: 833-5.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
6. Homey B, Müller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2: 175-84.
7. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer--much more than directing cell movement. Int J Dev Biol 2004; 48: 489-96.
8. Burger JA, Kipps TJ. CXCR4: a key receptor in the cross talk between tumor cells and their microenvironment. Blood 2006; 107: 1761-7.
9. Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2001; 2: 285-6.
10. Hall JM, Korach KS. Stromal cell-derived factor-1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003; 17: 792-803.
11. Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor-1 stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003; 63: 1969-74.
12. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
13. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997; 79: 1-8.
14. Boold CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
15. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82: 4-6.
16. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res 1986; 46: 467-73.
17. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996, 87: 2095-147.
18. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003, 100: 2645-50.
19. Shao J, Sheng H. Prostaglandin E2 induces the expression of IL-1alpha in colon cancer cells. J Immunol 2007, 178: 4097-103.
20. ten Kate M, Hofland LJ, van Grevenstein WM, van Koetsveld PV, Jeekel J, van Eijck CH. Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. Int J Cancer 2004, 112: 943-50.
21. Liu W, Reinmuth N, Stoeltzing O, et al. Cyclooxygenase-2 is upregulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 2003, 63: 3632-36.
22. Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y, Kusunoki M. Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology 2005, 68: 138-45.
23. Duque J, Diaz-Munoz MD, Fresno M, Iniguez MA. Up-regulation of cyclooxygenase-2 by interleukin-1beta in colon carcinoma cells. Cell Signal 2006, 18: 1262-69.
24. Sawai H, Funahashi H, Yamamoto M, et al. Interleukin-1alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer. Oncology 2003, 65: 167-73.
25. Sawai H, Okada Y, Funahashi H, et al. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol 2006, 7: 8.
26. Matsuo Y, Sawai H, Funahashi H, Takahashi H, Sakamoto M, Yamamoto M, et al. Enhanced angiogenesis due to inflammatory cytokines from pancreatic cancer cell lines and relation to metastatic potential. Pancreas 2004, 28: 344-52.
27. Matsuo Y, Sawai H, Ochi N, et al. Interleukin-1alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J Surg Res. 2009, 153: 274-81.
28. Grant DS, Kleinman HK, Goldberg ID et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90: 1937-41.
29. Kan M, Zang GH, Zarnegar R. Hepatocyte growth factor/ hepatopoietin a stimulates growth of rat kidney proximal tubular epithelial cell (RPTE), rat nonparenchymal liver cells, human melanoma cell, mouse keratinocytes and stimulates anchorageindependent growth of SV-40 transformed (RPTE). Biochem Biophys Res Commun 1991; 174: 331-7.
30. Bussolino F, DiRenzo MF, Ziche M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol; 1992; 119: 629-41.
31. Rosen EM, Laterra J, Joseph A, et al. Scatter factor expression and regulation inhuman glial tumors. Int. J Cancer 1996; 76: 248-55.
32. Nakamura T, Matsumoto K, Kiritoshi A, et al. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factor affects invasive growth of tumor cell: in vitro analysis of tumor-stromal interaction. Cancer Res 1997; 57: 152-9.
33. Maehara N, Nagai E, Mizumoto K, et al. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin Exp Metastasis 2002; 19: 417-26.
34. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67: 901-8.
35. Di Renzo MF, Poulsom R, Olivero M, et al. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995; 55: 1129-38.
36. Qian LW, Mizumoto K, Maehara N, et al. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 2003; 190: 105-12.
37. Xu D, Matsuo Y, Ma J, et al. Cancer cell-derived IL-1α promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells. J Surg Oncol 2010; 102(5): 469-77.
38. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-801.
39. Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995; 57: 752-62.
40. Murdoch C, Monk PN, Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999; 11: 704-12.
41. Chen Z, Colon I, Ortiz N, et al. Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res 1998; 58: 3668-76.
42. Wolf JS, Chen Z, Dong G, et al. IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001; 7: 1812-20.
43. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 59: 367-71.
44. Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151: 2667-75.
45. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-7.
46. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-33.
47. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
48. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999; 94: 3658-67.
49. Sanz-Rodríguez F, Hidalgo A, Teixidó J. Chemokine stromal cellderived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001; 97: 346-51.
50. Möhle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91: 4523-30.
51. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC-chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747-57.
52. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003; 63: 3833-9.
53. Wang J, Wang J, Sun Y, et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 2005; 17: 1578-92.
54. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 1: 1835-41.
55. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-8.
56. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004; 64: 8420-7.
57. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997; 22: 251-6.
58. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
59. Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004; 90: 1555-62.
60. David Roodman G. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 2003; 97: 733-8.
61. Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000; 165: 5269-77.
62. Lane BR, Strieter RM, Coffey MJ, Markovitz DM. Human immunodeficiency virus type 1 (HIV-1)-induced GRO-alpha production stimulates HIV-1 replication in macrophages and T lymphocytes. J Virol 2001; 75: 5812-22.
63. Loukinova E, Dong G, Enamorado-Ayalya I, et al. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 2000; 19: 3477-86.
64. Luan J, Shattuck-Brandt R, Haghnegahdar H, et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997; 62: 588-97.
65. Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998; 102: 465-72.
66. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004; 172: 2853-60.
67. Wislez M, Fujimoto N, Izzo JG, et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 2006; 66: 4198-207.
68. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growthrelated oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006; 66: 3071-7.
69. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005; 175: 5351-7.
70. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G proteincoupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 2005; 65: 2738-45.
71. Matsuo Y, Raimondo M, Woodward TA, et al. CXCchemokine/ CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009; 125: 1027-37.